Last 12 quarters of trend data · Healthcare · Medical - Pharmaceuticals
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.09 | — | — | — | — | — | 0.22 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.20 | 5.03 | — | — | — | — | 13.45 | 187.44 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.20 | 0.96 | 0.75 | 0.59 | 2.12 | 0.40 | 51.85 | 58.38 | 72.25 | 48.39 | — | 83.94 | 236.62 |
| — | +140.9% | -98.6% | -99.0% | -97.1% | -99.2% | — | -30.4% | -69.5% | — | — | — | — | |
| P/FCF | 0.24 | — | — | — | — | 0.04 | 29.42 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 539.64 | — | — | — | — | 16.42 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 16.64 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 85.9% | — | — | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| — | -14.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -7.2% | -14.0% | — | — | — | 99.1% | 79.8% | -512.6% | — | — | — | — | — |
| — | -114.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -2.4% | -417.7% | — | — | — | 141.8% | 75.1% | -293.2% | — | — | — | — | — |
| — | -394.5% | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.6% | -18.2% | -1.7% | 13.2% | -72.4% | -54.1% | 94.6% | -20.4% | -6.9% | -23.0% | — | -29.0% | -50.1% |
| — | +66.5% | -101.8% | +164.9% | -956.0% | -135.4% | — | +29.6% | +86.3% | — | — | — | — | |
| ROA | -1.0% | -15.4% | -1.4% | 8.7% | -42.3% | -40.1% | 77.0% | -15.3% | -4.7% | -14.5% | — | -21.6% | -37.3% |
| — | +61.5% | -101.8% | +157.2% | -803.3% | -175.4% | — | +29.3% | +87.4% | — | — | — | — | |
| ROIC | -13.4% | -1.7% | -10.0% | -139.1% | -197.8% | -93.6% | 160.2% | -43.7% | -54.7% | -54.3% | — | -40.1% | -69.3% |
| — | +98.2% | -106.2% | -218.5% | -261.3% | -72.4% | — | -9.0% | +21.0% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | 0.05 | 0.01 |
| — | -82.2% | -82.5% | -88.4% | -36.5% | -49.7% | — | -73.2% | 0.0% | — | — | — | — | |
| Debt / EBITDA | — | 19.43 | — | — | — | — | 0.01 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.56 | 27.85 | 14.31 | 9.04 | 2.72 | 3.56 | 11.01 | 2.06 | 3.30 | 3.45 | — | 3.81 | 3.30 |
| — | +681.5% | +30.0% | +338.7% | -17.6% | +3.4% | — | -45.9% | -0.0% | — | — | — | — | |
| Quick Ratio | 3.56 | 27.85 | 14.31 | 9.04 | 2.72 | 3.56 | 11.01 | 2.06 | 3.30 | 3.45 | — | 3.81 | 3.30 |
| — | +681.5% | +30.0% | +338.7% | -17.6% | +3.4% | — | -45.9% | -0.0% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEUP stock.
Neuphoria Therapeutics Inc.'s current P/E is -15.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Neuphoria Therapeutics Inc.'s current operating margin is -7.2%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neuphoria Therapeutics Inc.'s business trajectory between earnings reports.